CAPItello-290 Phase III trial of Truqap/paclitaxel combo (Il Sole 24 Ore Radiocor) - London, 18 Jun - Anglo-Swedish drug company AstraZeneca said that the CAPItello-290 Phase III trial for Truqap ...
(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Tuesday that the CAPItello-290 Phase III trial for Truqap (capivasertib) plus chemotherapy in patients with locally advanced ...
Collectively, mutations in PIK3CA, AKT1, and alterations in PTEN affect approximately 35% of patients with TNBC. The safety profile of Truqap plus paclitaxel was broadly consistent with the known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback